IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 46.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,338 shares of the medical research company's stock after selling 10,500 shares during the quarter. Dai ichi Life Insurance Company Ltd's holdings in IQVIA were worth $2,924,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the third quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA during the second quarter worth about $29,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IQV shares. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Trading Up 0.1 %

IQVIA stock traded up $0.21 during trading on Wednesday, hitting $201.44. The company's stock had a trading volume of 822,728 shares, compared to its average volume of 1,177,509. The stock's fifty day moving average is $220.36 and its 200 day moving average is $226.57. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.